BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11849197)

  • 21. CYP3A activity in European American and Japanese men using midazolam as an in vivo probe.
    Tateishi T; Watanabe M; Nakura H; Asoh M; Shirai H; Mizorogi Y; Kobayashi S; Thummel KE; Wilkinson GR
    Clin Pharmacol Ther; 2001 May; 69(5):333-9. PubMed ID: 11372001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice.
    Greenblatt DJ; von Moltke LL; Harmatz JS; Chen G; Weemhoff JL; Jen C; Kelley CJ; LeDuc BW; Zinny MA
    Clin Pharmacol Ther; 2003 Aug; 74(2):121-9. PubMed ID: 12891222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers.
    Bartoli A; Gatti G; Cipolla G; Barzaghi N; Veliz G; Fattore C; Mumford J; Perucca E
    Epilepsia; 1997 Jun; 38(6):702-7. PubMed ID: 9186253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping.
    Streetman DS; Kashuba AD; Bertino JS; Kulawy R; Rocci ML; Nafziger AN
    Pharmacogenetics; 2001 Jun; 11(4):349-55. PubMed ID: 11434513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
    Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
    J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the selective AMPA modulator NBI-1065845 on the pharmacokinetics of midazolam or ethinyl estradiol-levonorgestrel in healthy adults.
    Lin S; Ionescu A; Maynard-Scott J; Kennedy M; Walling DP; Furey M; Singh JB
    Clin Transl Sci; 2024 May; 17(5):e13791. PubMed ID: 38700236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.
    Pinto AG; Wang YH; Chalasani N; Skaar T; Kolwankar D; Gorski JC; Liangpunsakul S; Hamman MA; Arefayene M; Hall SD
    Clin Pharmacol Ther; 2005 Mar; 77(3):178-88. PubMed ID: 15735612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate.
    Kharasch ED; Whittington D; Hoffer C
    Anesthesiology; 2004 Sep; 101(3):729-37. PubMed ID: 15329598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
    Kharasch ED; Hoffer C; Whittington D; Sheffels P
    Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
    Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
    Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity.
    Eap CB; Buclin T; Cucchia G; Zullino D; Hustert E; Bleiber G; Golay KP; Aubert AC; Baumann P; Telenti A; Kerb R
    Eur J Clin Pharmacol; 2004 Jun; 60(4):237-46. PubMed ID: 15114429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
    Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
    Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
    Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
    Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam.
    Ibrahim A; Karim A; Feldman J; Kharasch E
    Anesth Analg; 2002 Sep; 95(3):667-73, table of contents. PubMed ID: 12198057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
    Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
    J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Midazolam and cortisol metabolism before and after CYP3A induction in humans.
    Eeckhoudt SL; Desager JP; Robert AR; Leclercq I; Verbeeck RK; Horsmans Y
    Int J Clin Pharmacol Ther; 2001 Jul; 39(7):293-9. PubMed ID: 11471773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can oral midazolam predict oral cyclosporine disposition?
    Paine MF; Davis CL; Shen DD; Marsh CL; Raisys VA; Thummel KE
    Eur J Pharm Sci; 2000 Nov; 12(1):51-62. PubMed ID: 11121733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single plasma sampling to predict oral clearance of CYP3A probe midazolam.
    Zhu B; Ou-Yang DS; Cheng ZN; Huang SL; Zhou HH
    Acta Pharmacol Sin; 2001 Jul; 22(7):634-8. PubMed ID: 11749829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Open-label, nonrandomized study of the effects of gatifloxacin on the pharmacokinetics of midazolam in healthy male volunteers.
    Grasela DM; LaCreta FP; Kollia GD; Randall DM; Uderman HD
    Pharmacotherapy; 2000 Mar; 20(3):330-5. PubMed ID: 10730688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.